Help Us Make Breakthroughs on Focal Epilepsy Treatment 

Our research study is evaluating the efficacy and safety of a new investigational treatment option for adults experiencing focal onset seizures. 

Those who qualify and choose to participate could earn up to $575 in 10 visits over approximately 23 weeks. 

AdobeStock_558629122-1

About the Study 

This study is looking at how well the study drug, PRAX-628, works for treating focal seizures compared to placebo, as well as its safety and side effects compared with placebo. 

If you qualify and choose to participate, there is a 50% chance you will receive the study drug and a 50% chance you will receive a placebo. A placebo is an inactive material that looks like PRAX-628 but does not contain any active study drug.  

You will be on this study for about 23 weeks which will include a screening period, a treatment period, and a follow-up period. You will be required to come into the clinic for up to 3 visits. You will also have 2 home health visits and attend up to 4 remote (over the phone) visits.  

Why Should I Participate?

Those who qualify and choose to participate could receive: 

Access to the investigational treatment medication at no cost 

Access to our top-tier team of board-certified physicians at no cost 

Compensation up to $575 for completing 10 visits over 23 weeks 

Study Criteria 

To qualify to participate you must: 

  • Be aged 18-75 years old 
  • Be experiencing focal onset seizures 
  • Report at least 4 seizures in the 4 weeks prior to screening 
  • Currently be taking at least 1 anti-seizure medication 
  • Not have epilepsy surgery planned during the course of the study 
  • Not have a history of neurosurgery for seizures less than a year prior to enrollment 
  • Not have a history of radiosurgery less than 2 years prior to enrollment 
  • Not have a history of VNS implantation 
  • Not have any serious mental health disorders 
AdobeStock_280768256-1

 

Find out if you qualify

Frequently asked questions

What is a research study or clinical trial?

A research study or clinical trial is the process a potential new drug, device, procedure, or process goes through to prove that it is safe, tolerable and effective for the condition it is being studied for. Research studies are the only way to advance medicine for future generations. 

Who can participate in a research study?

Each study has its own set of inclusion and exclusion criteria that a participant must meet before they are allowed to participate in a study. Patients from all backgrounds and walks of life are encouraged to participate 

What is Informed Consent?

Every participant in every research study must go through the informed consent process. During this, the trial doctor and research team go over what will happen in the study, what treatments you might get, how long the trial is expected to last, what happens during visits, the potential risks and benefits, and many other important facts about the study. Participants may withdraw their consent and discontinue the study at any time for any reason. 

What is a Placebo?

A placebo looks like a treatment but does not have any active medicine in it. Researchers use placebos to help make sure any changes in the participants’ health are actually caused by the study treatment. You do not get to choose if you get the study treatment or the placebo, and you may not know if you get the placebo until after the study. Not all research studies use a placebo. 

Why is Diversity Important?

If studies do not include diverse participants, we cannot know if treatments work for everyone who needs them. Studies only tell researchers how something works for the participants of that study, and they may not work the same in people of different races, ethnicities, ages, or sexes. 

How am I Protected?

All research studies must follow federal laws and ethical guidelines, including HIPAA. Studies must also be approved by an expert group called an institutional review board (IRB) that helps make sure the trial is fair and as safe as possible, and that any risks to the participants are worth the potential benefits.